Middle East And Africa Antiviral Drugs Market
Tamanho do mercado em biliões de dólares
CAGR :
% 
 Período de previsão |
2024 –2030 |
 Tamanho do mercado (ano base ) | |
 Tamanho do mercado ( Ano de previsão) | USD 2,225.82 |
 CAGR |
% |
| Principais participantes do mercado |
>Mercado de medicamentos antivirais no Médio Oriente e em África, por indicação (gripe, vírus da imunodeficiência humana (VIH), vírus da hepatite C (VHC), vírus sincicial respiratório, vírus herpes simplex, citomegalovírus humano (VHC), vírus varicela-zóster ( VZV), hepatite Vírus B (HBV), infecção por coronavírus e outros), tipo de doente (criança, adulto e geriátrico), produtos (oral, tópico e parentérico), tipo de medicamento (genérico e de marca), utilizador final ( hospitais, clínicas, domicílios Saúde , Centros de Especialidades, Centros de Ambulatório e Outros), Canal de Distribuição (Farmácia Hospitalar, Farmácia Online e Farmácia de Retalho) - Tendências e Previsões do Sector para 2030.
Análise e insights do mercado de medicamentos antivirais no Médio Oriente e em África
A crescente consciencialização sobre as infeções virais no Médio Oriente e em África aumentou a procura pelo mercado. O aumento dos gastos em saúde para melhores serviços de saúde também contribui para o crescimento do mercado. Os principais players do mercado concentram-se em diversos lançamentos e aprovações de serviços durante este período crucial. Além disso, o aumento do avanço das técnicas de desenvolvimento de medicamentos também contribui para o aumento da procura de medicamentos antivirais.
O mercado de medicamentos antivirais no Médio Oriente e em África deverá crescer no ano previsto devido ao aumento dos participantes no mercado e à disponibilidade de serviços avançados. A par disto, os fabricantes estão empenhados na atividade de desenvolvimento para o lançamento de novos serviços no mercado. O crescente desenvolvimento no campo do desenvolvimento de medicamentos está a impulsionar ainda mais o crescimento do mercado. No entanto, dificuldades como a falta de protocolos padronizados e a falta de profissionais qualificados podem dificultar o crescimento do mercado de medicamentos antivirais no Médio Oriente e em África no período de previsão.
Espera-se que o aumento dos gastos em saúde no avanço e desenvolvimento de medicamentos dê oportunidades ao mercado. No entanto, a crescente utilização de tratamentos alternativos pode desafiar o crescimento do mercado. A Data Bridge Market Research analisa que o mercado de medicamentos antivirais no Médio Oriente e em África deverá atingir o valor de 2.225,82 milhões de dólares até 2030, com um CAGR de 2,9% durante o período de previsão.
|
Métrica de reporte |
Detalhes |
|
Período de previsão |
2023 a 2030 |
|
Ano base |
2022 |
|
Anos históricos |
2021 (personalizável para 2015-2020) |
|
Unidades Quantitativas |
Receita em milhões, volumes em unidades e preços em dólares americanos |
|
Segmentos cobertos |
Indicação (Influenza, Vírus da Imunodeficiência Humana (VIH), Vírus da Hepatite C (HCV), Vírus Sincicial Respiratório, Vírus Herpes Simplex, Citomegalovírus Humano (HCMV), Vírus Varicela-Zoster (VZV), Vírus da Hepatite B (HBV), Infeção por Coronavírus, e outros), tipo de doente (criança, adulto e geriátrico), produtos (oral, tópico e parentérico), tipo de medicamento (genérico e de marca), utilizador final (hospitais, clínicas, assistência médica domiciliária, centros especializados, centros de ambulatório e Outros), Canal de Distribuição (Farmácia Hospitalar, Farmácia Online e Farmácia de Retalho) |
|
Países abrangidos |
África do Sul, Arábia Saudita, Emirados Árabes Unidos, Egito, Israel, Kuwait e Resto do Médio Oriente e África |
|
Participantes do mercado abrangidos |
Gilead Sciences, Inc., F. Hoffmann-La Roche Ltd, GLAXOSMITHKLINE PLC, Abbvie, Merck & Co., Inc., Johnson & Johnson Services, Inc., Bristol-Myers Squibb Company, Cipla Inc., Aurobindo Pharma, Dr. Reddy's Laboratories Ltd., Zydus Pharmaceuticals, Inc., Mylan Pharmaceuticals ULC, Teva Pharmaceuticals USA, Inc., EMERGENT, Sun Pharmaceutical Industries Ltd., Avet Pharmaceuticals Inc., Pfizer Inc., SIGA Technologies, NAVINTA LLC., Macleods Pharmaceuticals Ltd. , BioCryst Pharmaceuticals, Inc e Hetero. entre outros |
Definição do mercado de medicamentos antivirais no Médio Oriente e em África
Os medicamentos antivirais são medicamentos utilizados para tratar infeções virais, inibindo a replicação dos vírus nas células hospedeiras. Estes medicamentos têm como alvo vírus ou tipos de vírus específicos e atuam impedindo o vírus de entrar na célula hospedeira ou bloqueando enzimas ou proteínas essenciais necessárias para a replicação viral. Ao contrário dos antibióticos, que são utilizados para tratar infeções bacterianas, os medicamentos antivirais são geralmente menos eficazes, uma vez que os vírus têm uma estrutura muito mais simples e dependem das células hospedeiras para se replicarem. No entanto, podem ainda ser úteis no tratamento de algumas infeções virais, como a gripe, o herpes e o VIH.
Dinâmica do mercado de medicamentos antivirais no Médio Oriente e em África
Esta secção trata da compreensão dos impulsionadores, oportunidades, restrições e desafios do mercado. Tudo isto é discutido em detalhe abaixo:
Motoristas
- Aumento da prevalência de infeções virais
As infeções virais têm vindo a aumentar constantemente em todo o mundo durante as últimas décadas. Um vírus que entra no corpo, explora as suas células para replicação e se espalha causa uma infeção viral. As infeções virais podem resultar em vários sintomas, desde menores a maiores e, em alguns casos, até sintomas fatais. A globalização é uma das principais causas do aumento das infeções virais. As pessoas viajam e comunicam entre si através de fronteiras, tornando o mundo mais ligado do que nunca. A transmissão viral de uma área para outra acelerou devido a esta conectividade melhorada.
Assim, a crescente prevalência de infecções virais é uma questão complexa com muitos factores contribuintes. A globalização, a densidade populacional, as alterações climáticas e a resistência aos antibióticos influenciam a propagação dos vírus. Por conseguinte, espera-se que impulsione o crescimento do mercado.
- Avanços no desenvolvimento de novos medicamentos antivirais
Os tratamentos antivirais são prescritos para doentes com infeções virais. A criação de novos medicamentos antivirais tem feito enormes progressos ao longo do tempo. Estes desenvolvimentos reduziram o fardo das doenças, melhoraram o tratamento de infeções virais e salvaram vidas. Há muito desenvolvimento no campo dos novos medicamentos antivirais.
Assim, os avanços no desenvolvimento de novos medicamentos antivirais melhoraram o tratamento de infeções virais, reduziram a carga da doença e deverão impulsionar o crescimento do mercado.
Restrição
- Custo elevado dos medicamentos antivirais
O elevado custo dos medicamentos antivirais pode ter implicações significativas para os doentes e para os sistemas de saúde. Os doentes que não podem pagar estes medicamentos podem ficar sem tratamento ou depender de tratamentos de qualidade inferior, levando a piores resultados de saúde. Além disso, o elevado custo dos medicamentos antivirais pode sobrecarregar os orçamentos dos cuidados de saúde, especialmente em países com recursos limitados.
Assim, prevê-se que o elevado custo dos medicamentos antivirais restrinja o mercado dos medicamentos antivirais no Médio Oriente e em África.
Oportunidade
-
Aumento de novos sistemas de distribuição de medicamentos
A investigação sobre medicamentos antivirais enfatizou a criação de novos mecanismos de distribuição de medicamentos. Relativamente às técnicas convencionais de administração de medicamentos, os novos sistemas de administração apresentam vários benefícios, como uma melhor biodisponibilidade, administração personalizada de medicamentos e menos efeitos adversos.
Assim, o desenvolvimento de novos sistemas de distribuição de medicamentos é uma importante área de investigação em medicamentos antivirais. Os sistemas de distribuição de fármacos em nanopartículas, hidrogéis, dendrímeros, microagulhas e peptídeos de penetração celular são alguns sistemas promissores de distribuição de fármacos que têm sido investigados para fármacos antivirais. Estes sistemas de administração oferecem diversas vantagens em relação aos métodos tradicionais de administração de medicamentos e têm o potencial de melhorar a eficácia e a segurança dos medicamentos antivirais e deverão criar uma oportunidade no crescimento do mercado.
Desafio
- Caducidade da patente de medicamentos antivirais
O processo de expiração da patente faz com que o desenvolvedor original ou o titular da patente perca o direito exclusivo de produzir e comercializar um medicamento específico. A expiração da patente dos medicamentos antivirais pode ter um impacto significativo no negócio farmacêutico, uma vez que pode convidar à concorrência dos produtores de medicamentos genéricos.
As patentes dos medicamentos antivirais expiram no final do período em que o seu criador tem o direito exclusivo de fabricar e comercializar o medicamento. Após a expiração da patente de um medicamento, outros produtores podem criar e comercializar versões genéricas. Isto pode resultar em maior concorrência e em preços mais baixos para o consumidor. O VIH, hepatite B e C, herpes, gripe e outras doenças virais são tratadas com medicamentos antivirais. As patentes de medicamentos antivirais expiram em momentos diferentes, dependendo do medicamento e do país. As patentes de medicamentos são normalmente concedidas por 20 anos a partir da data do depósito. Outros produtores são livres de criar e comercializar versões genéricas de medicamentos quando a sua patente expirar. Como o produtor não tem de gastar tanto em marketing, investigação e desenvolvimento e estudos clínicos, os medicamentos genéricos são muitas vezes mais acessíveis do que os medicamentos de marca.
Assim, a expiração de patentes de medicamentos antivirais pode ter implicações significativas para a disponibilidade, acessibilidade e acessibilidade destes medicamentos importantes e espera-se que atue como um desafio ao crescimento do mercado.
Desenvolvimentos recentes
- Em janeiro de 2023, a Merck, conhecida como MSD, anunciou a conclusão bem-sucedida da oferta pública em dinheiro, através de uma subsidiária, para todas as ações ordinárias em circulação da Imago Biosciences, Inc. 36,00 USD por ação em dinheiro, sem juros e sujeito a dedução de qualquer retenção de imposto exigida. A aquisição ajudará no crescimento da receita.
- Em abril de 2021, a Zydus Pharmaceuticals, Inc. anunciou que tinha recebido aprovação restrita de utilização de emergência do Controlador Geral de Medicamentos da Índia (DCGI) para utilizar o medicamento antiviral Virafin para o tratamento de infeções moderadas por COVID-19. Isto ajudará a empresa a aumentar a sua presença e reputação no Médio Oriente e em África noutras regiões do globo.
Âmbito do mercado de medicamentos antivirais no Médio Oriente e em África
O mercado de medicamentos antivirais do Médio Oriente e África está segmentado em seis segmentos notáveis com base na indicação, tipo de paciente, produtos, tipo de medicamento, utilizador final e canal de distribuição. O crescimento entre segmentos ajuda-o a analisar os nichos de crescimento e as estratégias para abordar o mercado e determinar as suas principais áreas de aplicação e a diferença nos seus mercados-alvo.
Indicação
- Gripe
- Vírus da Imunodeficiência Humana (VIH)
- Vírus da Hepatite C
- Vírus Herpes Simplex
- Citomegalovírus Humano (HCMV)
- Vírus Varicela-Zoster (VZV)
- Vírus da Hepatite B
- Vírus sincicial respiratório
- Contágio do coronavírus
- Outros
Com base na indicação, o mercado de medicamentos antivirais do Médio Oriente e África está segmentado em gripe, vírus da imunodeficiência humana (VIH), vírus da hepatite C (VHC), vírus sincicial respiratório, vírus herpes simplex, citomegalovírus humano (VHC) , vírus da varicela-zóster (VZV), vírus da hepatite B (HBV), infeção por coronavírus e outros.
Tipo de paciente
- Criança
- Adulto
- Geriátrico
Com base no tipo de paciente, o mercado de medicamentos antivirais do Médio Oriente e África está segmentado em infantil, adulto e geriátrico.
PRODUTOS
- Oral
- Tópico
- Parenteral
Com base nos produtos, o mercado de medicamentos antivirais do Médio Oriente e de África está segmentado em oral, tópico e parentérico.
Tipo de droga
- Genérico
- Com marca
Com base no tipo de medicamento, o mercado de medicamentos antivirais no Médio Oriente e em África está segmentado em genéricos e de marca.
Utilizador final
- Hospital
- Clínicas
- Cuidados de Saúde Domiciliários
- Centros Especializados
- Centros Ambulatórios
- Outros
Com base no utilizador final, o mercado de medicamentos antivirais do Médio Oriente e África está segmentado em hospitais, clínicas, cuidados domiciliários, centros especializados, centros de ambulatório, entre outros.
Canal de distribuição
- Farmácia Hospitalar
- Farmácia on-line
- Farmácia de Retalho
Com base no canal de distribuição, o mercado de medicamentos antivirais do Médio Oriente e África está segmentado em farmácia hospitalar, farmácia online e farmácia de retalho.
Análise/perspetivas regionais do mercado de medicamentos antivirais no Médio Oriente e em África
O mercado de medicamentos antivirais do Médio Oriente e de África está categorizado em seis segmentos notáveis com base na indicação, tipo de paciente, produtos, tipo de medicamento, utilizador final e canal de distribuição.
Os países abordados neste relatório de mercado são a África do Sul, Arábia Saudita, Emirados Árabes Unidos, Egito, Israel, Kuwait e Resto do Médio Oriente e África.
Em 2023, a África do Sul domina a região do Médio Oriente e de África devido à forte presença de intervenientes-chave e à crescente procura dos mercados emergentes e à expansão.
A secção do país do relatório também fornece fatores individuais de impacto no mercado e alterações na regulamentação do mercado interno que impactam as tendências atuais e futuras do mercado. Dados como novas vendas, vendas de reposição, demografia do país, atos regulamentares e tarifas de importação e exportação são alguns dos principais indicadores utilizados para prever o cenário de mercado para países individuais. Além disso, são considerados a presença e disponibilidade de marcas do Médio Oriente e de África e os desafios enfrentados devido à concorrência grande ou escassa de marcas locais e nacionais, e o impacto dos canais de vendas, ao mesmo tempo que se fornece uma análise de previsão dos dados do país.
Cenário competitivo e análise da quota de mercado de medicamentos antivirais no Médio Oriente e África
O panorama competitivo do mercado de medicamentos antivirais no Médio Oriente e em África fornece detalhes por concorrente. Os detalhes incluídos são a visão geral da empresa, finanças da empresa, receitas geradas, potencial de mercado, investimento em I&D, novas iniciativas de mercado, localizações e instalações de produção, pontos fortes e fracos da empresa, lançamento de produtos, aprovações de produtos, largura e fôlego do produto, domínio de aplicação e tipo de produto curva da linha de vida. Os dados acima fornecidos estão apenas relacionados com o foco da empresa no mercado de medicamentos antivirais do Médio Oriente e de África.
Alguns dos principais players que operam no mercado de medicamentos antivirais do Médio Oriente e de África são a Gilead Sciences, Inc., a F. Hoffmann-La Roche Ltd, a GLAXOSMITHKLINE PLC, a Abbvie, a Merck & Co., Inc., a Johnson & Johnson Services, Inc. , Bristol-Myers Squibb Company, Cipla Inc., Aurobindo Pharma, Dr. , Pfizer Inc., SIGA Technologies, NAVINTA LLC., Macleods Pharmaceuticals Ltd., BioCryst Pharmaceuticals, Inc e Hetero, entre outras.
SKU-
Obtenha acesso online ao relatório sobre a primeira nuvem de inteligência de mercado do mundo
- Painel interativo de análise de dados
- Painel de análise da empresa para oportunidades de elevado potencial de crescimento
- Acesso de analista de pesquisa para personalização e customização. consultas
- Análise da concorrência com painel interativo
- Últimas notícias, atualizações e atualizações Análise de tendências
- Aproveite o poder da análise de benchmark para um rastreio abrangente da concorrência
Índice
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF THE MIDDLE EAST AND AFRICA ANTIVIRAL DRUGS MARKET
1.4 LIMITATIONS
1.5 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 CURRENCY AND PRICING
2.5 DBMR TRIPOD DATA VALIDATION MODEL
2.6 MULTIVARIATE MODELLING
2.7 PRODUCT TYPE LIFELINE CURVE
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.9 DBMR MARKET POSITION GRID
2.1 MARKET TESTING TYPE COVERAGE GRID
2.11 VENDOR SHARE ANALYSIS
2.12 SECONDARY SOURCES
2.13 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 PORTER’S FIVE FORCES
4.2 PESTEL ANALYSIS
5 EPIDEMIOLOGY
6 PIPELINE ANALYSIS FOR MIDDLE EAST AND AFRICA ANTIVIRAL DRUGS MARKET
7 REGULATORY FRAMEWORK
8 MARKET OVERVIEW
8.1 DRIVERS
8.1.1 RISING PREVALENCE OF VIRAL INFECTIONS
8.1.2 ADVANCEMENTS IN NEW ANTIVIRAL DRUG DEVELOPMENT
8.1.3 GROWING DEMAND FOR COMBINATION THERAPIES
8.1.4 INCREASING GOVERNMENT FUNDING AND R&D ACTIVITIES
8.2 RESTRAINS
8.2.1 HIGH COST OF ANTIVIRAL DRUGS
8.2.2 EMERGENCE OF DRUG-RESISTANT STRAINS OF VIRUSES
8.3 OPPORTUNITIES
8.3.1 INCREASING COLLABORATION AND PARTNERSHIP AMONG KEY PLAYERS
8.3.2 RISING NOVEL DRUG DELIVERY SYSTEMS
8.3.3 DEVELOPMENT OF PERSONALIZED MEDICINES
8.4 CHALLENGES
8.4.1 PATENT EXPIRATION OF ANTIVIRAL DRUGS
8.4.2 DEMAND FOR ALTERNATIVE MEDICINES
9 MIDDLE EAST AND AFRICA ANTIVIRAL DRUGS MARKET, BY INDICATION
9.1 OVERVIEW
9.2 INFLUENZA
9.2.1 NEURAMINIDASE INHIBITORS
9.2.1.1 OSELTAMIVIR
9.2.1.2 ZANAMIVIR
9.2.1.3 PERAMIVIR
9.2.1.4 LANINAMIVIR
9.2.2 M2 INHIBITORS
9.2.2.1 RIMANTADINE
9.2.2.2 OTHERS
9.2.3 RNA POLYMERASE INHIBITORS
9.2.3.1 FAVIPIRAVIR
9.2.3.2 BALOXAVIR MARBOXIL
9.3 HUMAN IMMUNODEFICIENCY VIRUS (HIV)
9.3.1 REVERSE TRANSCRIPTASE INHIBITORS
9.3.1.1 NUCLEOSIDE (NRTIS)
9.3.1.1.1 LAMIVUDINE
9.3.1.1.2 ABACAVIR
9.3.1.1.3 DIDANOSINE
9.3.1.1.4 OTHERS
9.3.1.2 NONNUCLEOSIDE (NNRTIS)
9.3.1.2.1 EFAVIRENZ
9.3.1.2.2 NEVIRAPINE
9.3.1.2.3 DELAVIRDINE
9.3.1.2.4 OTHERS
9.3.1.3 INTEGRASE
9.3.1.3.1 DOLUTEGRAVIR
9.3.1.3.2 ELVITEGRAVIR
9.3.1.3.3 RALTEGRAVIR
9.3.1.3.4 BICTEGRAVIR
9.3.1.4 NUCLEOTIDE
9.3.1.4.1 TENOFOVIR
9.3.1.4.2 OTHERS
9.3.1.5 INTERFERONS
9.3.1.5.1 ALPHA
9.3.1.5.2 BETA
9.3.1.5.3 GAMMA
9.3.1.6 GP41
9.3.1.6.1 ENFUVIRTIDE
9.3.1.6.2 OTHERS
9.3.2 PROTEASE
9.3.2.1 ATAZANAVIR
9.3.2.2 DARUNAVIR
9.3.2.3 LOPINAVIR
9.3.2.4 RITONAVIR
9.3.2.5 SAQUINAVIR
9.3.2.6 INDINAVIR
9.3.2.7 NELFINAVIR
9.3.2.8 TIPRANAVIR
9.3.2.9 AMPRENAVIR
9.4 HEPATITIS C VIRUS
9.4.1 NS5B POLYMERASE
9.4.1.1 SOFOSBUVIR
9.4.1.2 DASABUVIR
9.4.2 NS3/4A PROTEASE
9.4.2.1 DANOPREVIR
9.4.2.2 GLECAPREVIR
9.4.2.3 GRAZOPREVIR
9.4.2.4 PARITAPREVIR
9.4.2.5 SIMEPREVIR
9.4.3 NS5A PHOSPHOPROTEIN
9.4.3.1 LEDIPASVIR
9.4.3.2 VELPATASVIR
9.4.3.3 OMBITASVIR
9.4.3.4 ELBASVIR
9.4.3.5 DACLATASVIR
9.4.3.6 PIBRENTASVIR
9.4.4 NEURAMINIDASE
9.4.4.1 OSELTAMIVIR
9.4.4.2 ZANAMIVIR
9.4.4.3 PERAMIVIR
9.4.4.4 LANINAMIVIR
9.4.5 RNA POLYMERASE
9.4.5.1 BALOXAVIR MARBOXIL
9.4.5.2 FAVIPIRAVIR
9.4.6 MATRIX PROTEIN 2
9.4.6.1 RIMATIDINE
9.4.6.2 FAVIPIRAVIR
9.5 HERPES SIMPLEX VIRUS
9.5.1 DNA POLYMERASE UL30
9.5.1.1 ACICLOVIR
9.5.1.2 FAMCICLOVIR
9.5.1.3 VALACICLOVIR
9.5.1.4 PENCICLOVIR TRIFLURIDINE
9.5.1.5 BRIVUDINE
9.5.1.6 FOSCARNET
9.5.1.7 IDOXURIDINE
9.5.2 ENVELOPE PROTEINS
9.5.2.1 DOCOSANOL
9.5.2.2 OTHERS
9.6 HUMAN CYTOMEGALOVIRUS (HCMV)
9.6.1 GANCICLOVIR
9.6.2 VALGANCICLOVIR
9.6.3 CIDOFOVIR
9.6.4 FOSCARNET
9.6.5 FOMIVIRSEN
9.7 VARICELLA-ZOSTER VIRUS (VZV)
9.7.1 VALACICLOVIR
9.7.2 FAMCICLOVIR
9.7.3 ACICLOVIR
9.7.4 VIDARABINE
9.7.5 BRIVUDINE
9.8 HEPATITIS B VIRUS
9.8.1 ENTECAVIR
9.8.2 TENOFOVIR
9.8.3 TELBIVUDINE
9.8.4 TENOFOVIR ALAFENAMIDE
9.8.5 OTHERS
9.9 RESPIRATORY SYNCYTIAL VIRUS
9.9.1 RNA POLYMERASE
9.9.1.1 RIBAVIRIN
9.9.1.2 OTHERS
9.9.2 FUSION GLYCOPROTEIN
9.9.2.1 PALIVIZUMAB
9.9.2.2 OTHERS
9.1 CORONAVIRUS INFECTION
9.11 OTHERS
10 MIDDLE EAST AND AFRICA ANTIVIRAL DRUGS MARKET, BY PATIENT TYPE
10.1 OVERVIEW
10.2 GERIATRIC
10.2.1 MALE
10.2.2 FEMALE
10.3 CHILD
10.3.1 MALE
10.3.2 FEMALE
10.4 ADULT
10.4.1 MALE
10.4.2 FEMALE
11 MIDDLE EAST AND AFRICA ANTIVIRAL DRUGS MARKET, BY PRODUCTS
11.1 OVERVIEW
11.2 ORAL
11.2.1 SOLID
11.2.1.1 TABLETS
11.2.1.2 CAPSULES
11.2.1.3 OTHERS
11.2.2 SEMISOLID
11.2.2.1 GELS
11.2.2.2 EMULSIONS
11.2.2.3 ELIXIRS
11.2.2.4 OTHERS
11.2.3 LIQUID
11.2.3.1 SOLUTIONS
11.2.3.2 SYRUPS
11.2.3.3 OTHERS
11.3 TOPICAL
11.3.1 SEMI-SOLID
11.3.1.1 CREAM
11.3.1.2 OINTMENT
11.3.1.3 GELS
11.3.1.4 OTHERS
11.3.2 LIQUID
11.3.2.1 SOLUTIONS
11.3.2.2 SUSPENSIONS
11.3.3 SOLID
11.3.3.1 POWDERS
11.3.3.2 SUPPOSITORIES
11.3.3.3 ENEMA
11.3.3.4 OTHERS
11.4 PARENTERAL
11.4.1 CONVENTIONAL DRUG DELIVERY FORMUALTIONS
11.4.1.1 SOLUTIONS
11.4.1.2 RECONSTITUTED/LYOPHILIZED
11.4.1.3 SUSPENSIONS
11.4.1.4 EMULSIONS
11.4.1.5 OTHERS
11.4.2 NOVEL DRUG DELIVERY FORMULATIONS
11.4.3 COLLOIDAL DISPERSIONS
11.4.4 LONG ACTING INJECTION FORMULATION
12 MIDDLE EAST AND AFRICA ANTIVIRAL DRUGS MARKET, BY DRUG TYPE
12.1 OVERVIEW
12.2 GENERIC
12.3 BRANDED
13 MIDDLE EAST AND AFRICA ANTIVIRAL DRUGS MARKET, BY END USER
13.1 OVERVIEW
13.2 HOSPITAL
13.3 SPECIALTY CENTERS
13.4 AMBULATORY CENTRES
13.5 CLINICS
13.6 HOME HEALTHCARE
13.7 OTHERS
14 MIDDLE EAST AND AFRICA ANTIVIRAL DRUGS MARKET, BY DISTRIBUTION CHANNEL
14.1 OVERVIEW
14.2 HOSPITAL PHARMACY
14.3 RETAIL PHARMACY
14.4 ONLINE PHARMACY
15 MIDDLE EAST AND AFRICA ANTIVIRAL DRUGS MARKET, BY REGION
15.1 MIDDLE EAST AND AFRICA
15.1.1 SOUTH AFRICA
15.1.2 SAUDI ARABIA
15.1.3 UAE
15.1.4 EGYPT
15.1.5 KUWAIT
15.1.6 ISRAEL
15.1.7 REST OF MIDDLE EAST AND AFRICA
16 MIDDLE EAST AND AFRICA ANTIVIRAL DRUGS MARKET: COMPANY LANDSCAPE
16.1 COMPANY SHARE ANALYSIS: MIDDLE EAST AND AFRICA
17 SWOT ANALYSIS
18 COMPANY PROFILE
18.1 GILEAD SCIENCES, INC. (2022)
18.1.1 COMPANY SNAPSHOT
18.1.2 REVENUE ANALYSIS
18.1.3 COMPANY SHARE ANALYSIS
18.1.4 PRODUCT PORTFOLIO
18.1.5 RECENT DEVELOPMENT
18.2 PFIZER INC. (2022)
18.2.1 COMPANY SNAPSHOT
18.2.2 REVENUE ANALYSIS
18.2.3 COMPANY SHARE ANALYSIS
18.2.4 PRODUCT PORTFOLIO
18.2.5 RECENT DEVELOPMENTS
18.3 SIGA TECHNOLOGIES (2022)
18.3.1 COMPANY SNAPSHOT
18.3.2 REVENUE ANALYSIS
18.3.3 COMPANY SHARE ANALYSIS
18.3.4 PRODUCT PORTFOLIO
18.3.5 RECENT DEVELOPMENT
18.4 GLAXOSMITHKLINE PLC.
18.4.1 COMPANY SNAPSHOT
18.4.2 REVENUE ANALYSIS
18.4.3 COMPANY SHARE ANALYSIS
18.4.4 PRODUCT PORTFOLIO
18.4.5 RECENT DEVELOPMENT
18.5 F. HOFFMANN-LA ROCHE LTD. (2022)
18.5.1 COMPANY SNAPSHOT
18.5.2 REVENUE ANALYSIS
18.5.3 COMPANY SHARE ANALYSIS
18.5.4 PRODUCT PORTFOLIO
18.5.5 RECENT DEVELOPMENT
18.6 ABBVIE INC.
18.6.1 COMPANY SNAPSHOT
18.6.2 REVENUE ANALYSIS
18.6.3 PRODUCT PORTFOLIO
18.6.4 RECENT DEVELOPMENT
18.7 AUROBINDO PHARMA (2022)
18.7.1 COMPANY SNAPSHOT
18.7.2 REVENUE ANALYSIS
18.7.3 PRODUCT PORTFOLIO
18.7.4 RECENT DEVELOPMENT
18.8 AVET PHARMACEUTICALS INC.
18.8.1 COMPANY SNAPSHOT
18.8.2 PRODUCT PORTFOLIO
18.8.3 RECENT DEVELOPMENT
18.9 BRISTOLL MYERS SQUIBB (2022)
18.9.1 COMPANY SNAPSHOT
18.9.2 REVENUE ANALYSIS
18.9.3 PRODUCT PORTFOLIO
18.9.4 RECENT DEVELOPMENT
18.1 BIOCRYST PHARMACEUTICALS, INC. (2022)
18.10.1 COMPANY SNAPSHOT
18.10.2 REVENUE ANALYSIS
18.10.3 PRODUCT PORTFOLIO
18.10.4 RECENT DEVELOPMENT
18.11 CIPLA INC. (2022)
18.11.1 COMPANY SNAPSHOT
18.11.2 REVENUE ANALYSIS
18.11.3 PRODUCT PORTFOLIO
18.11.4 RECENT DEVELOPMENT
18.12 DR. REDDY’S LABORATORIES LTD. (2022)
18.12.1 COMPANY SNAPSHOT
18.12.2 REVENUE ANALYSIS
18.12.3 PRODUCT PORTFOLIO
18.12.4 RECENT DEVELOPMENTS
18.13 EMERGENT (2022)
18.13.1 COMPANY SNAPSHOT
18.13.2 REVENUE ANALYSIS
18.13.3 PRODUCT PORTFOLIO
18.13.4 RECENT DEVELOPMENT
18.14 HETERO.
18.14.1 COMPANY SNAPSHOT
18.14.2 PRODUCT PORTFOLIO
18.14.3 RECENT DEVELOPMENT
18.15 JOHNSON & JOHNSON PRIVATE LIMITED (2022)
18.15.1 COMPANY SNAPSHOT
18.15.2 REVENUE ANALYSIS
18.15.3 PRODUCT PORTFOLIO
18.15.4 RECENT DEVELOPMENT
18.16 MACLEODS PHARMACEUTICALS LTD.
18.16.1 COMPANY SNAPSHOT
18.16.2 PRODUCT PORTFOLIO
18.16.3 RECENT DEVELOPMENT
18.17 MERCK & CO., INC, (2022)
18.17.1 COMPANY SNAPSHOT
18.17.2 REVENUE ANALYSIS
18.17.3 PRODUCT PORTFOLIO
18.17.4 RECENT DEVELOPMENT
18.18 MYLAN N.V (SUBSIDIARY OF VIATRIS) (2022)
18.18.1 COMPANY SNAPSHOT
18.18.2 REVENUE ANALYSIS
18.18.3 PRODUCT PORTFOLIO
18.18.4 RECENT DEVELOPMENT
18.19 NAVINTA LLC.
18.19.1 COMPANY SNAPSHOT
18.19.2 PRODUCT PORTFOLIO
18.19.3 RECENT DEVELOPMENT
18.2 SUN PHARMACEUTICAL INDUSTRIES LTD. (2022)
18.20.1 COMPANY SNAPSHOT
18.20.2 REVENUE ANALYSIS
18.20.3 PRODUCT PORTFOLIO
18.20.4 RECENT DEVELOPMENT
18.21 TEVA PHARMACEUTICAL INDUSTRIES LTD. (2022)
18.21.1 COMPANY SNAPSHOT
18.21.2 REVENUE ANALYSIS
18.21.3 PRODUCT PORTFOLIO
18.21.4 RECENT DEVELOPMENT
18.22 ZYDUS PHARMACEUTICALS, INC. (2022)
18.22.1 COMPANY SNAPSHOT
18.22.2 REVENUE ANALYSIS
18.22.3 PRODUCT PORTFOLIO
18.22.4 RECENT DEVELOPMENTS
19 QUESTIONNAIRE
20 RELATED REPORTS
Lista de Tabela
TABLE 1 MIDDLE EAST AND AFRICA ANTIVIRAL DRUGS MARKET, BY INDICATION, 2021- 2030 (USD MILLION)
TABLE 2 MIDDLE EAST AND AFRICA INFLUENZA IN ANTIVIRAL DRUGS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 3 MIDDLE EAST AND AFRICA INFLUENZA IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 4 MIDDLE EAST AND AFRICA NEURAMINIDASE INHIBITORS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 5 MIDDLE EAST AND AFRICA M2 INHIBITORS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 6 MIDDLE EAST AND AFRICA M2 INHIBITORS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 7 MIDDLE EAST AND AFRICA HUMAN IMMUNODEFICIENCY VIRUS (HIV) IN ANTIVIRAL DRUGS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 8 MIDDLE EAST AND AFRICA HUMAN IMMUNODEFICIENCY VIRUS (HIV) IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 9 MIDDLE EAST AND AFRICA REVERSE TRANSCRIPTASE INHIBITORS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 10 MIDDLE EAST AND AFRICA NUCLEOSIDE (NRTIS) IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 11 MIDDLE EAST AND AFRICA NONNUCLEOSIDE (NNRTIS) IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 12 MIDDLE EAST AND AFRICA INTEGRASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 13 MIDDLE EAST AND AFRICA NUCLEOTIDE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 14 MIDDLE EAST AND AFRICA INTERFERONS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 15 MIDDLE EAST AND AFRICA GP41 IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 16 MIDDLE EAST AND AFRICA PROTEASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 17 MIDDLE EAST AND AFRICA HEPATITIS C VIRUS IN ANTIVIRAL DRUGS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 18 MIDDLE EAST AND AFRICA HEPATITIS C VIRUS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 19 MIDDLE EAST AND AFRICA NS5B POLYMERASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 20 MIDDLE EAST AND AFRICA NS3/4A PROTEASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 21 MIDDLE EAST AND AFRICA NS5A PHOSPHOPROTEIN IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 22 MIDDLE EAST AND AFRICA NEURAMINIDASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 23 MIDDLE EAST AND AFRICA RNA POLYMERASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 24 MIDDLE EAST AND AFRICA MATRIX PROTEIN 2 IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 25 MIDDLE EAST AND AFRICA HERPES SIMPLEX VIRUS IN ANTIVIRAL DRUGS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 26 MIDDLE EAST AND AFRICA HERPES SIMPLEX VIRUS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 27 MIDDLE EAST AND AFRICA DNA POLYMERASE UL30 IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 28 MIDDLE EAST AND AFRICA ENVELOPE PROTEINS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 29 MIDDLE EAST AND AFRICA HUMAN CYTOMEGALOVIRUS (HCMV) IN ANTIVIRAL DRUGS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 30 MIDDLE EAST AND AFRICA HUMAN CYTOMEGALOVIRUS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 31 MIDDLE EAST AND AFRICA VARICELLA-ZOSTER VIRUS (VZV) IN ANTIVIRAL DRUGS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 32 MIDDLE EAST AND AFRICA DNA POLYMERASE ADEFOVIR IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 33 MIDDLE EAST AND AFRICA HEPATITIS B VIRUS IN ANTIVIRAL DRUGS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 34 MIDDLE EAST AND AFRICA DNA POLYMERASE ADEFOVIR IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 35 MIDDLE EAST AND AFRICA RESPIRATORY SYNCYTIAL VIRUS IN ANTIVIRAL DRUGS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 36 MIDDLE EAST AND AFRICA RESPIRATORY SYNCYTICAL VIRUS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 37 MIDDLE EAST AND AFRICA RNA POLYMERASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 38 MIDDLE EAST AND AFRICA FUSION GLYCOPROTEIN IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 39 MIDDLE EAST AND AFRICA CORONAVIRUS INFECTION IN ANTIVIRAL DRUGS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 40 MIDDLE EAST AND AFRICA OTHERS IN ANTIVIRAL DRUGS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 41 MIDDLE EAST AND AFRICA ANTIVIRAL DRUGS MARKET, BY PATIENT TYPE, 2021- 2030 (USD MILLION)
TABLE 42 MIDDLE EAST AND AFRICA GERIATRIC IN ANTIVIRAL DRUGS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 43 MIDDLE EAST AND AFRICA GERIATRIC IN ANTIVIRAL DRUGS MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)
TABLE 44 MIDDLE EAST AND AFRICA CHILD IN ANTIVIRAL DRUGS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 45 MIDDLE EAST AND AFRICA CHILD IN ANTIVIRAL DRUGS MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)
TABLE 46 MIDDLE EAST AND AFRICA ADULT IN ANTIVIRAL DRUGS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 47 MIDDLE EAST AND AFRICA ADULT IN ANTIVIRAL DRUGS MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)
TABLE 48 MIDDLE EAST AND AFRICA ANTIVIRAL DRUGS MARKET, BY PRODUCT, 2021- 2030 (USD MILLION)
TABLE 49 MIDDLE EAST AND AFRICA ORAL IN ANTIVIRAL DRUGS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 50 MIDDLE EAST AND AFRICA ORAL IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 51 MIDDLE EAST AND AFRICA SOLID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 52 MIDDLE EAST AND AFRICA SEMI-SOLID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 53 MIDDLE EAST AND AFRICA LIQUID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 54 MIDDLE EAST AND AFRICA TOPICAL IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 55 MIDDLE EAST AND AFRICA TOPICAL IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 56 MIDDLE EAST AND AFRICA SEMI-SOLID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 57 MIDDLE EAST AND AFRICA LIQUID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 58 MIDDLE EAST AND AFRICA SOLID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 59 MIDDLE EAST AND AFRICA PARENTERAL IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 60 MIDDLE EAST AND AFRICA PARENTERAL IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 61 MIDDLE EAST AND AFRICA CONVENTIONAL DRUG DELIVERY FORMULATIONS IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 62 MIDDLE EAST AND AFRICA NOVEL DRUG DELIVERY FORMULATIONS IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 63 MIDDLE EAST AND AFRICA ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021- 2030 (USD MILLION)
TABLE 64 MIDDLE EAST AND AFRICA ANTIVIRAL DRUGS MARKET, BY END USER, 2021- 2030 (USD MILLION)
TABLE 65 MIDDLE EAST AND AFRICA ANTIVIRAL DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021- 2030 (USD MILLION)
TABLE 66 MIDDLE EAST AND AFRICA ANTIVIRAL DRUGS MARKET, BY COUNTRY, 2021-2030 (USD MILLION)
TABLE 67 MIDDLE EAST AND AFRICA ANTIVIRAL DRUGS MARKET, BY INDICATION, 2021-2030 (USD MILLION)
TABLE 68 MIDDLE EAST AND AFRICA INFLUENZA IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 69 MIDDLE EAST AND AFRICA NEURAMINIDASE INHIBITORS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 70 MIDDLE EAST AND AFRICA M2 INHIBITORS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 71 MIDDLE EAST AND AFRICA RNA POLYMERASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 72 MIDDLE EAST AND AFRICA HUMAN IMMUNODEFICIENCY VIRUS (HIV) IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 73 MIDDLE EAST AND AFRICA REVERSE TRANSCRIPTASE INHIBITORS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 74 MIDDLE EAST AND AFRICA NUCLEOSIDE (NRTIS) IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 75 MIDDLE EAST AND AFRICA NONNUCLEOSIDE (NNRTIS) IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 76 MIDDLE EAST AND AFRICA INTEGRASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 77 MIDDLE EAST AND AFRICA NUCLEOTIDE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 78 MIDDLE EAST AND AFRICA INTERFERONS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 79 MIDDLE EAST AND AFRICA GP41 IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 80 MIDDLE EAST AND AFRICA PROTEASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 81 MIDDLE EAST AND AFRICA HEPATITIS C VIRUS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 82 MIDDLE EAST AND AFRICA NS5B POLYMERASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 83 MIDDLE EAST AND AFRICA NS3/4A PROTEASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 84 MIDDLE EAST AND AFRICA NS5A PHOSPHOPROTEIN IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 85 MIDDLE EAST AND AFRICA NEURAMINIDASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 86 MIDDLE EAST AND AFRICA RNA POLYMERASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 87 MIDDLE EAST AND AFRICA MATRIX PROTEIN 2 IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 88 MIDDLE EAST AND AFRICA HERPES SIMPLEX VIRUS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 89 MIDDLE EAST AND AFRICA DNA POLYMERASE UL30 IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 90 MIDDLE EAST AND AFRICA ENVELOPE PROTEINS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 91 MIDDLE EAST AND AFRICA HUMAN CYTOMEGALOVIRUS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 92 MIDDLE EAST AND AFRICA VARICELLA-ZOSTER VIRUS (VZV) IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 93 MIDDLE EAST AND AFRICA DNA POLYMERASE ADEFOVIR IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 94 MIDDLE EAST AND AFRICA RESPIRATORY SYNCYTICAL VIRUS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 95 MIDDLE EAST AND AFRICA RNA POLYMERASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 96 MIDDLE EAST AND AFRICA FUSION GLYCOPROTEIN IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 97 MIDDLE EAST AND AFRICA ANTIVIRAL DRUGS MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)
TABLE 98 MIDDLE EAST AND AFRICA GERIATRIC IN ANTIVIRAL DRUGS MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)
TABLE 99 MIDDLE EAST AND AFRICA CHILD IN ANTIVIRAL DRUGS MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)
TABLE 100 MIDDLE EAST AND AFRICA ADULT IN ANTIVIRAL DRUGS MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)
TABLE 101 MIDDLE EAST AND AFRICA ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 102 MIDDLE EAST AND AFRICA ORAL IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 103 MIDDLE EAST AND AFRICA SOLID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 104 MIDDLE EAST AND AFRICA SEMI-SOLID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 105 MIDDLE EAST AND AFRICA LIQUID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 106 MIDDLE EAST AND AFRICA TOPICAL IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 107 MIDDLE EAST AND AFRICA SEMI-SOLID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 108 MIDDLE EAST AND AFRICA LIQUID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 109 MIDDLE EAST AND AFRICA SOLID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 110 MIDDLE EAST AND AFRICA PARENTERAL IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 111 MIDDLE EAST AND AFRICA CONVENTIONAL DRUG DELIVERY FORMULATIONS IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 112 MIDDLE EAST AND AFRICA NOVEL DRUG DELIVERY FORMULATIONS IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 113 MIDDLE EAST AND AFRICA ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 114 MIDDLE EAST AND AFRICA ANTIVIRAL DRUGS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 115 MIDDLE EAST AND AFRICA ANTIVIRAL DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 116 SOUTH AFRICA ANTIVIRAL DRUGS MARKET, BY INDICATION, 2021-2030 (USD MILLION)
TABLE 117 SOUTH AFRICA INFLUENZA IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 118 SOUTH AFRICA NEURAMINIDASE INHIBITORS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 119 SOUTH AFRICA M2 INHIBITORS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 120 SOUTH AFRICA RNA POLYMERASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 121 SOUTH AFRICA HUMAN IMMUNODEFICIENCY VIRUS (HIV) IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 122 SOUTH AFRICA REVERSE TRANSCRIPTASE INHIBITORS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 123 SOUTH AFRICA NUCLEOSIDE (NRTIS) IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 124 SOUTH AFRICA NONNUCLEOSIDE (NNRTIS) IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 125 SOUTH AFRICA INTEGRASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 126 SOUTH AFRICA NUCLEOTIDE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 127 SOUTH AFRICA INTERFERONS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 128 SOUTH AFRICA GP41 IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 129 SOUTH AFRICA PROTEASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 130 SOUTH AFRICA HEPATITIS C VIRUS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 131 SOUTH AFRICA NS5B POLYMERASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 132 SOUTH AFRICA NS3/4A PROTEASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 133 SOUTH AFRICA NS5A PHOSPHOPROTEIN IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 134 SOUTH AFRICA NEURAMINIDASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 135 SOUTH AFRICA RNA POLYMERASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 136 SOUTH AFRICA MATRIX PROTEIN 2 IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 137 SOUTH AFRICA HERPES SIMPLEX VIRUS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 138 SOUTH AFRICA DNA POLYMERASE UL30 IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 139 SOUTH AFRICA ENVELOPE PROTEINS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 140 SOUTH AFRICA HUMAN CYTOMEGALOVIRUS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 141 SOUTH AFRICA VARICELLA-ZOSTER VIRUS (VZV) IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 142 SOUTH AFRICA DNA POLYMERASE ADEFOVIR IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 143 SOUTH AFRICA RESPIRATORY SYNCYTICAL VIRUS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 144 SOUTH AFRICA RNA POLYMERASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 145 SOUTH AFRICA FUSION GLYCOPROTEIN IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 146 SOUTH AFRICA ANTIVIRAL DRUGS MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)
TABLE 147 SOUTH AFRICA GERIATRIC IN ANTIVIRAL DRUGS MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)
TABLE 148 SOUTH AFRICA CHILD IN ANTIVIRAL DRUGS MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)
TABLE 149 SOUTH AFRICA ADULT IN ANTIVIRAL DRUGS MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)
TABLE 150 SOUTH AFRICA ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 151 SOUTH AFRICA ORAL IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 152 SOUTH AFRICA SOLID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 153 SOUTH AFRICA SEMI-SOLID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 154 SOUTH AFRICA LIQUID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 155 SOUTH AFRICA TOPICAL IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 156 SOUTH AFRICA SEMI-SOLID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 157 SOUTH AFRICA LIQUID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 158 SOUTH AFRICA SOLID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 159 SOUTH AFRICA PARENTERAL IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 160 SOUTH AFRICA CONVENTIONAL DRUG DELIVERY FORMULATIONS IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 161 SOUTH AFRICA NOVEL DRUG DELIVERY FORMULATIONS IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 162 SOUTH AFRICA ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 163 SOUTH AFRICA ANTIVIRAL DRUGS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 164 SOUTH AFRICA ANTIVIRAL DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 165 SAUDI ARABIA ANTIVIRAL DRUGS MARKET, BY INDICATION, 2021-2030 (USD MILLION)
TABLE 166 SAUDI ARABIA INFLUENZA IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 167 SAUDI ARABIA NEURAMINIDASE INHIBITORS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 168 SAUDI ARABIA M2 INHIBITORS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 169 SAUDI ARABIA RNA POLYMERASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 170 SAUDI ARABIA HUMAN IMMUNODEFICIENCY VIRUS (HIV) IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 171 SAUDI ARABIA REVERSE TRANSCRIPTASE INHIBITORS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 172 SAUDI ARABIA NUCLEOSIDE (NRTIS) IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 173 SAUDI ARABIA NONNUCLEOSIDE (NNRTIS) IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 174 SAUDI ARABIA INTEGRASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 175 SAUDI ARABIA NUCLEOTIDE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 176 SAUDI ARABIA INTERFERONS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 177 SAUDI ARABIA GP41 IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 178 SAUDI ARABIA PROTEASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 179 SAUDI ARABIA HEPATITIS C VIRUS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 180 SAUDI ARABIA NS5B POLYMERASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 181 SAUDI ARABIA NS3/4A PROTEASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 182 SAUDI ARABIA NS5A PHOSPHOPROTEIN IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 183 SAUDI ARABIA NEURAMINIDASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 184 SAUDI ARABIA RNA POLYMERASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 185 SAUDI ARABIA MATRIX PROTEIN 2 IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 186 SAUDI ARABIA HERPES SIMPLEX VIRUS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 187 SAUDI ARABIA DNA POLYMERASE UL30 IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 188 SAUDI ARABIA ENVELOPE PROTEINS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 189 SAUDI ARABIA HUMAN CYTOMEGALOVIRUS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 190 SAUDI ARABIA VARICELLA-ZOSTER VIRUS (VZV) IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 191 SAUDI ARABIA DNA POLYMERASE ADEFOVIR IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 192 SAUDI ARABIA RESPIRATORY SYNCYTICAL VIRUS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 193 SAUDI ARABIA RNA POLYMERASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 194 SAUDI ARABIA FUSION GLYCOPROTEIN IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 195 SAUDI ARABIA ANTIVIRAL DRUGS MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)
TABLE 196 SAUDI ARABIA GERIATRIC IN ANTIVIRAL DRUGS MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)
TABLE 197 SAUDI ARABIA CHILD IN ANTIVIRAL DRUGS MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)
TABLE 198 SAUDI ARABIA ADULT IN ANTIVIRAL DRUGS MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)
TABLE 199 SAUDI ARABIA ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 200 SAUDI ARABIA ORAL IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 201 SAUDI ARABIA SOLID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 202 SAUDI ARABIA SEMI-SOLID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 203 SAUDI ARABIA LIQUID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 204 SAUDI ARABIA TOPICAL IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 205 SAUDI ARABIA SEMI-SOLID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 206 SAUDI ARABIA LIQUID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 207 SAUDI ARABIA SOLID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 208 SAUDI ARABIA PARENTERAL IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 209 SAUDI ARABIA CONVENTIONAL DRUG DELIVERY FORMULATIONS IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 210 SAUDI ARABIA NOVEL DRUG DELIVERY FORMULATIONS IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 211 SAUDI ARABIA ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 212 SAUDI ARABIA ANTIVIRAL DRUGS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 213 SAUDI ARABIA ANTIVIRAL DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 214 U.A.E ANTIVIRAL DRUGS MARKET, BY INDICATION, 2021-2030 (USD MILLION)
TABLE 215 U.A.E INFLUENZA IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 216 U.A.E NEURAMINIDASE INHIBITORS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 217 U.A.E M2 INHIBITORS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 218 U.A.E RNA POLYMERASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 219 U.A.E HUMAN IMMUNODEFICIENCY VIRUS (HIV) IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 220 U.A.E REVERSE TRANSCRIPTASE INHIBITORS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 221 U.A.E NUCLEOSIDE (NRTIS) IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 222 U.A.E NONNUCLEOSIDE (NNRTIS) IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 223 U.A.E INTEGRASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 224 U.A.E NUCLEOTIDE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 225 U.A.E INTERFERONS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 226 U.A.E GP41 IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 227 U.A.E PROTEASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 228 U.A.E HEPATITIS C VIRUS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 229 U.A.E NS5B POLYMERASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 230 U.A.E NS3/4A PROTEASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 231 U.A.E NS5A PHOSPHOPROTEIN IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 232 U.A.E NEURAMINIDASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 233 U.A.E RNA POLYMERASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 234 U.A.E MATRIX PROTEIN 2 IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 235 U.A.E HERPES SIMPLEX VIRUS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 236 U.A.E DNA POLYMERASE UL30 IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 237 U.A.E ENVELOPE PROTEINS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 238 U.A.E HUMAN CYTOMEGALOVIRUS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 239 U.A.E VARICELLA-ZOSTER VIRUS (VZV) IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 240 U.A.E DNA POLYMERASE ADEFOVIR IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 241 U.A.E RESPIRATORY SYNCYTICAL VIRUS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 242 U.A.E RNA POLYMERASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 243 U.A.E FUSION GLYCOPROTEIN IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 244 U.A.E ANTIVIRAL DRUGS MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)
TABLE 245 U.A.E GERIATRIC IN ANTIVIRAL DRUGS MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)
TABLE 246 U.A.E CHILD IN ANTIVIRAL DRUGS MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)
TABLE 247 U.A.E ADULT IN ANTIVIRAL DRUGS MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)
TABLE 248 U.A.E ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 249 U.A.E ORAL IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 250 U.A.E SOLID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 251 U.A.E SEMI-SOLID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 252 U.A.E LIQUID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 253 U.A.E TOPICAL IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 254 U.A.E SEMI-SOLID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 255 U.A.E LIQUID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 256 U.A.E SOLID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 257 U.A.E PARENTERAL IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 258 UAECONVENTIONAL DRUG DELIVERY FORMULATIONS IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 259 U.A.E NOVEL DRUG DELIVERY FORMULATIONS IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 260 U.A.E ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 261 U.A.E ANTIVIRAL DRUGS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 262 U.A.E ANTIVIRAL DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 263 EGYPT ANTIVIRAL DRUGS MARKET, BY INDICATION, 2021-2030 (USD MILLION)
TABLE 264 EGYPT INFLUENZA IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 265 EGYPT NEURAMINIDASE INHIBITORS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 266 EGYPT M2 INHIBITORS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 267 EGYPT RNA POLYMERASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 268 EGYPT HUMAN IMMUNODEFICIENCY VIRUS (HIV) IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 269 EGYPT REVERSE TRANSCRIPTASE INHIBITORS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 270 EGYPT NUCLEOSIDE (NRTIS) IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 271 EGYPT NONNUCLEOSIDE (NNRTIS) IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 272 EGYPT INTEGRASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 273 EGYPT NUCLEOTIDE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 274 EGYPT INTERFERONS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 275 EGYPT GP41 IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 276 EGYPT PROTEASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 277 EGYPT HEPATITIS C VIRUS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 278 EGYPT NS5B POLYMERASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 279 EGYPT NS3/4A PROTEASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 280 EGYPT NS5A PHOSPHOPROTEIN IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 281 EGYPT MATRIX PROTEIN 2 IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 282 EGYPT HERPES SIMPLEX VIRUS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 283 EGYPT DNA POLYMERASE UL30 IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 284 EGYPT ENVELOPE PROTEINS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 285 EGYPT HUMAN CYTOMEGALOVIRUS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 286 EGYPT VARICELLA-ZOSTER VIRUS (VZV) IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 287 EGYPT DNA POLYMERASE ADEFOVIR IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 288 EGYPT RESPIRATORY SYNCYTICAL VIRUS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 289 EGYPT RNA POLYMERASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 290 EGYPT FUSION GLYCOPROTEIN IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 291 EGYPT ANTIVIRAL DRUGS MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)
TABLE 292 EGYPT GERIATRIC IN ANTIVIRAL DRUGS MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)
TABLE 293 EGYPT CHILD IN ANTIVIRAL DRUGS MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)
TABLE 294 EGYPT ADULT IN ANTIVIRAL DRUGS MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)
TABLE 295 EGYPT ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 296 EGYPT ORAL IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 297 EGYPT SOLID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 298 EGYPT SEMI-SOLID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 299 EGYPT LIQUID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 300 EGYPT TOPICAL IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 301 EGYPT SEMI-SOLID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 302 EGYPT LIQUID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 303 EGYPT SOLID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 304 EGYPT PARENTERAL IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 305 EGYPT CONVENTIONAL DRUG DELIVERY FORMULATIONS IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 306 EGYPT NOVEL DRUG DELIVERY FORMULATIONS IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 307 EGYPT ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 308 EGYPT ANTIVIRAL DRUGS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 309 EGYPT ANTIVIRAL DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 310 KUWAIT ANTIVIRAL DRUGS MARKET, BY INDICATION, 2021-2030 (USD MILLION)
TABLE 311 KUWAIT INFLUENZA IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 312 KUWAIT NEURAMINIDASE INHIBITORS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 313 KUWAIT M2 INHIBITORS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 314 KUWAIT RNA POLYMERASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 315 KUWAIT HUMAN IMMUNODEFICIENCY VIRUS (HIV) IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 316 KUWAIT REVERSE TRANSCRIPTASE INHIBITORS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 317 KUWAIT NUCLEOSIDE (NRTIS) IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 318 KUWAIT NONNUCLEOSIDE (NNRTIS) IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 319 KUWAIT INTEGRASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 320 KUWAIT NUCLEOTIDE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 321 KUWAIT INTERFERONS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 322 KUWAIT GP41 IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 323 KUWAIT PROTEASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 324 KUWAIT HEPATITIS C VIRUS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 325 KUWAIT NS5B POLYMERASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 326 KUWAIT NS3/4A PROTEASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 327 KUWAIT NS5A PHOSPHOPROTEIN IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 328 KUWAIT NEURAMINIDASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 329 KUWAIT RNA POLYMERASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 330 KUWAIT MATRIX PROTEIN 2 IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 331 KUWAIT HERPES SIMPLEX VIRUS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 332 KUWAIT DNA POLYMERASE UL30 IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 333 KUWAIT ENVELOPE PROTEINS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 334 KUWAIT HUMAN CYTOMEGALOVIRUS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 335 KUWAIT VARICELLA-ZOSTER VIRUS (VZV) IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 336 KUWAIT DNA POLYMERASE ADEFOVIR IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 337 KUWAIT RESPIRATORY SYNCYTICAL VIRUS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 338 KUWAIT RNA POLYMERASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 339 KUWAIT FUSION GLYCOPROTEIN IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 340 KUWAIT ANTIVIRAL DRUGS MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)
TABLE 341 KUWAIT GERIATRIC IN ANTIVIRAL DRUGS MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)
TABLE 342 KUWAIT CHILD IN ANTIVIRAL DRUGS MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)
TABLE 343 KUWAIT ADULT IN ANTIVIRAL DRUGS MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)
TABLE 344 KUWAIT ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 345 KUWAIT ORAL IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 346 KUWAIT SOLID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 347 KUWAIT SEMI-SOLID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 348 KUWAIT LIQUID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 349 KUWAIT TOPICAL IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 350 KUWAIT SEMI-SOLID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 351 KUWAIT LIQUID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 352 KUWAIT SOLID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 353 KUWAIT PARENTERAL IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 354 KUWAIT CONVENTIONAL DRUG DELIVERY FORMULATIONS IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 355 KUWAIT NOVEL DRUG DELIVERY FORMULATIONS IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 356 KUWAIT ANTIVIRAL DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 357 ISRAEL ANTIVIRAL DRUGS MARKET, BY INDICATION, 2021-2030 (USD MILLION)
TABLE 358 ISRAEL INFLUENZA IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 359 ISRAEL NEURAMINIDASE INHIBITORS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 360 ISRAEL M2 INHIBITORS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 361 ISRAEL RNA POLYMERASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 362 ISRAEL HUMAN IMMUNODEFICIENCY VIRUS (HIV) IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 363 ISRAEL REVERSE TRANSCRIPTASE INHIBITORS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 364 ISRAEL NUCLEOSIDE (NRTIS) IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 365 ISRAEL NONNUCLEOSIDE (NNRTIS) IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 366 ISRAEL INTEGRASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 367 ISRAEL NUCLEOTIDE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 368 ISRAEL INTERFERONS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 369 ISRAEL GP41 IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 370 ISRAEL PROTEASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 371 ISRAEL HEPATITIS C VIRUS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 372 ISRAEL NS5B POLYMERASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 373 ISRAEL NS3/4A PROTEASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 374 ISRAEL NS5A PHOSPHOPROTEIN IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 375 ISRAEL NEURAMINIDASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 376 ISRAEL RNA POLYMERASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 377 ISRAEL MATRIX PROTEIN 2 IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 378 ISRAEL HERPES SIMPLEX VIRUS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 379 ISRAEL DNA POLYMERASE UL30 IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 380 ISRAEL ENVELOPE PROTEINS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 381 ISRAEL HUMAN CYTOMEGALOVIRUS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 382 ISRAEL VARICELLA-ZOSTER VIRUS (VZV) IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 383 ISRAEL DNA POLYMERASE ADEFOVIR IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 384 ISRAEL RESPIRATORY SYNCYTICAL VIRUS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 385 ISRAEL RNA POLYMERASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 386 ISRAEL FUSION GLYCOPROTEIN IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 387 ISRAEL ANTIVIRAL DRUGS MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)
TABLE 388 ISRAEL GERIATRIC IN ANTIVIRAL DRUGS MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)
TABLE 389 ISRAEL CHILD IN ANTIVIRAL DRUGS MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)
TABLE 390 ISRAEL ADULT IN ANTIVIRAL DRUGS MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)
TABLE 391 ISRAEL ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 392 ISRAEL ORAL IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 393 ISRAEL SOLID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 394 ISRAEL SEMI-SOLID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 395 ISRAEL LIQUID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 396 ISRAEL TOPICAL IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 397 ISRAEL SEMI-SOLID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 398 ISRAEL LIQUID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 399 ISRAEL SOLID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 400 ISRAEL PARENTERAL IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 401 ISRAEL CONVENTIONAL DRUG DELIVERY FORMULATIONS IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 402 ISRAEL NOVEL DRUG DELIVERY FORMULATIONS IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 403 ISRAEL ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 404 ISRAEL ANTIVIRAL DRUGS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 405 ISRAEL ANTIVIRAL DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 406 REST OF MIDDLE EAST AND AFRICA ANTIVIRAL DRUGS MARKET, BY INDICATION, 2021-2030 (USD MILLION)
Lista de Figura
FIGURE 1 MIDDLE EAST AND AFRICA ANTIVIRAL DRUGS: SEGMENTATION
FIGURE 2 MIDDLE EAST AND AFRICA ANTIVIRAL DRUGS MARKET: DATA TRIANGULATION
FIGURE 3 MIDDLE EAST AND AFRICA ANTIVIRAL DRUGS MARKET: DROC ANALYSIS
FIGURE 4 MIDDLE EAST AND AFRICA ANTIVIRAL DRUGS MARKET: MIDDLE EAST AND AFRICA VS REGIONAL MARKET ANALYSIS
FIGURE 5 MIDDLE EAST AND AFRICA ANTIVIRAL DRUGS MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 MIDDLE EAST AND AFRICA ANTIVIRAL DRUGS MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 7 MIDDLE EAST AND AFRICA ANTIVIRAL DRUGS MARKET: DBMR MARKET POSITION GRID
FIGURE 8 MIDDLE EAST AND AFRICA ANTIVIRAL DRUGS MARKET: MARKET TESTING TYPE COVERAGE GRID
FIGURE 9 MIDDLE EAST AND AFRICA ANTIVIRAL DRUGS MARKET: VENDOR SHARE ANALYSIS
FIGURE 10 MIDDLE EAST AND AFRICA ANTIVIRAL DRUGS MARKET: SEGMENTATION
FIGURE 11 THE RISING PREVALENCE OF VIRAL INFECTIONS IS EXPECTED TO DRIVE THE MIDDLE EAST AND AFRICA ANTIVIRAL DRUGS MARKET IN THE FORECAST PERIOD
FIGURE 12 THE INFLUENZA SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE MIDDLE EAST AND AFRICA ANTIVIRAL DRUGS MARKET IN 2023 & 2030
FIGURE 13 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF THE MIDDLE EAST AND AFRICA ANTIVIRAL DRUGS MARKET
FIGURE 14 MIDDLE EAST AND AFRICA ANTIVIRAL DRUGS MARKET: BY INDICATION , 2022
FIGURE 15 MIDDLE EAST AND AFRICA ANTIVIRAL DRUGS MARKET: BY INDICATION , 2023-2030 (USD MILLION)
FIGURE 16 MIDDLE EAST AND AFRICA ANTIVIRAL DRUGS MARKET: BY INDICATION , CAGR (2023-2030)
FIGURE 17 MIDDLE EAST AND AFRICA ANTIVIRAL DRUGS MARKET: BY INDICATION , LIFELINE CURVE
FIGURE 18 MIDDLE EAST AND AFRICA ANTIVIRAL DRUGS MARKET: BY PATIENT TYPE, 2022
FIGURE 19 MIDDLE EAST AND AFRICA ANTIVIRAL DRUGS MARKET: BY PATIENT TYPE, 2023-2030 (USD MILLION)
FIGURE 20 MIDDLE EAST AND AFRICA ANTIVIRAL DRUGS MARKET: BY PATIENT TYPE, CAGR (2023-2030)
FIGURE 21 MIDDLE EAST AND AFRICA ANTIVIRAL DRUGS MARKET: BY PATIENT TYPE, LIFELINE CURVE
FIGURE 22 MIDDLE EAST AND AFRICA ANTIVIRAL DRUGS MARKET: BY PRODUCT, 2022
FIGURE 23 MIDDLE EAST AND AFRICA ANTIVIRAL DRUGS MARKET: BY PRODUCT, 2023-2030 (USD MILLION)
FIGURE 24 MIDDLE EAST AND AFRICA ANTIVIRAL DRUGS MARKET: BY PRODUCT, CAGR (2023-2030)
FIGURE 25 MIDDLE EAST AND AFRICA ANTIVIRAL DRUGS MARKET: BY PRODUCT, LIFELINE CURVE
FIGURE 26 MIDDLE EAST AND AFRICA ANTIVIRAL DRUGS MARKET: BY DRUG TYPE, 2022
FIGURE 27 MIDDLE EAST AND AFRICA ANTIVIRAL DRUGS MARKET: BY DRUG TYPE, 2023-2030 (USD MILLION)
FIGURE 28 MIDDLE EAST AND AFRICA ANTIVIRAL DRUGS MARKET: BY DRUG TYPE, CAGR (2023-2030)
FIGURE 29 MIDDLE EAST AND AFRICA ANTIVIRAL DRUGS MARKET: BY DRUG TYPE, LIFELINE CURVE
FIGURE 30 MIDDLE EAST AND AFRICA ANTIVIRAL DRUGS MARKET: BY END USER, 2022
FIGURE 31 MIDDLE EAST AND AFRICA ANTIVIRAL DRUGS MARKET: BY END USER, 2023-2030 (USD MILLION)
FIGURE 32 MIDDLE EAST AND AFRICA ANTIVIRAL DRUGS MARKET: BY END USER, CAGR (2023-2030)
FIGURE 33 MIDDLE EAST AND AFRICA ANTIVIRAL DRUGS MARKET: BY END USER, LIFELINE CURVE
FIGURE 34 MIDDLE EAST AND AFRICA ANTIVIRAL DRUGS MARKET: BY DISTRIBUTION CHANNEL, 2022
FIGURE 35 MIDDLE EAST AND AFRICA ANTIVIRAL DRUGS MARKET: BY DISTRIBUTION CHANNEL, 2023-2030 (USD MILLION)
FIGURE 36 MIDDLE EAST AND AFRICA ANTIVIRAL DRUGS MARKET: BY DISTRIBUTION CHANNEL, CAGR (2023-2030)
FIGURE 37 MIDDLE EAST AND AFRICA ANTIVIRAL DRUGS MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE
FIGURE 38 MIDDLE EAST AND AFRICA ANTIVIRAL DRUGS MARKET: SNAPSHOT (2022)
FIGURE 39 MIDDLE EAST AND AFRICA ANTIVIRAL DRUGS MARKET: BY COUNTRY (2022)
FIGURE 40 MIDDLE EAST AND AFRICA ANTIVIRAL DRUGS MARKET: BY COUNTRY (2023 & 2030)
FIGURE 41 MIDDLE EAST AND AFRICA ANTIVIRAL DRUGS MARKET: BY COUNTRY (2022 & 2030)
FIGURE 42 MIDDLE EAST AND AFRICA ANTIVIRAL DRUGS MARKET: INDICATION (2023-2030)
FIGURE 43 MIDDLE EAST AND AFRICA ANTIVIRAL DRUGS MARKET: COMPANY SHARE 2022 (%)
Metodologia de Investigação
A recolha de dados e a análise do ano base são feitas através de módulos de recolha de dados com amostras grandes. A etapa inclui a obtenção de informações de mercado ou dados relacionados através de diversas fontes e estratégias. Inclui examinar e planear antecipadamente todos os dados adquiridos no passado. Da mesma forma, envolve o exame de inconsistências de informação observadas em diferentes fontes de informação. Os dados de mercado são analisados e estimados utilizando modelos estatísticos e coerentes de mercado. Além disso, a análise da quota de mercado e a análise das principais tendências são os principais fatores de sucesso no relatório de mercado. Para saber mais, solicite uma chamada de analista ou abra a sua consulta.
A principal metodologia de investigação utilizada pela equipa de investigação do DBMR é a triangulação de dados que envolve a mineração de dados, a análise do impacto das variáveis de dados no mercado e a validação primária (especialista do setor). Os modelos de dados incluem grelha de posicionamento de fornecedores, análise da linha de tempo do mercado, visão geral e guia de mercado, grelha de posicionamento da empresa, análise de patentes, análise de preços, análise da quota de mercado da empresa, normas de medição, análise global versus regional e de participação dos fornecedores. Para saber mais sobre a metodologia de investigação, faça uma consulta para falar com os nossos especialistas do setor.
Personalização disponível
A Data Bridge Market Research é líder em investigação formativa avançada. Orgulhamo-nos de servir os nossos clientes novos e existentes com dados e análises que correspondem e atendem aos seus objetivos. O relatório pode ser personalizado para incluir análise de tendências de preços de marcas-alvo, compreensão do mercado para países adicionais (solicite a lista de países), dados de resultados de ensaios clínicos, revisão de literatura, mercado remodelado e análise de base de produtos . A análise de mercado dos concorrentes-alvo pode ser analisada desde análises baseadas em tecnologia até estratégias de carteira de mercado. Podemos adicionar quantos concorrentes necessitar de dados no formato e estilo de dados que procura. A nossa equipa de analistas também pode fornecer dados em tabelas dinâmicas de ficheiros Excel em bruto (livro de factos) ou pode ajudá-lo a criar apresentações a partir dos conjuntos de dados disponíveis no relatório.
